StreetInsider.com News Articles

H.C. Wainwright Starts Eikon Therapeutics Inc. (EIKN) at Buy

Fri, 16 Oct 2026 06:08:49 -0400

H.C. Wainwright analyst Sara Nik initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Buy rating and a price target of $23.00.

For an analyst ratings summary and ratings history on Eikon Therapeutics Inc. click here. For more ratings news on Eikon Therapeutics Inc. click here.

Shares of Eikon Therapeutics Inc. closed at $7.54 yesterday.

Eikon Therapeutics files IND for prostate cancer drug EIK1006

Thu, 15 Oct 2026 08:01:19 -0400

Eikon Therapeutics, Inc. (Nasdaq: EIKN) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for EIK1006, a drug candidate for the treatment of advanced metastatic prostate cancer.

EIK1006 is an androgen receptor (AR) antagonist that the company states is structurally unrelated to currently available lutamide-class antagonists. According to the company, the candidate targets both wild-type androgen receptors and variants associated with resistance to existing prostate cancer therapies.

Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon, said the IND submission reflects the company's imaging platform, which he described as enabling

Eikon Therapeutics files IND for prostate cancer drug EIK1006

Thu, 15 Oct 2026 08:01:19 -0400

Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon, said the IND submission reflects the company's imaging platform, which he described as enabling

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

Thu, 15 Oct 2026 08:00:00 -0400

Internally-derived candidate targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies

MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists.

“The submission of an IND for EIK1006 demonstrates once again that

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

Thu, 15 Oct 2026 08:00:00 -0400

Internally-derived candidate targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies

“The submission of an IND for EIK1006 demonstrates once again that

Form SCHEDULE 13G/A Eikon Therapeutics, Inc. Filed by: FMR LLC

Wed, 07 Oct 2026 11:47:00 -0400

si-local-file:///var/storage/secattach/20261007/27159979.html

Form SCHEDULE 13G/A Eikon Therapeutics, Inc. Filed by: Abu Dhabi Investment Authority

Fri, 02 Oct 2026 11:14:00 -0400

si-local-file:///var/storage/secattach/20261002/27140152.html

Eikon Therapeutics names new chief scientific officer from Bristol Myers Squibb

Thu, 03 Sep 2026 07:30:42 -0400

Eikon Therapeutics, Inc. (Nasdaq: EIKN) has appointed Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer, the company announced in a press release.

Dr. Chang joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President and Head of Cardiovascular Discovery Biology and Translational Pharmacology. Before that role, he served as Head of Cardiovascular Research at Gilead Sciences and then as Vice President of Disease Biology at MyoKardia, where he worked on the characterization of mavacamten, a drug later approved for the treatment of hypertrophic cardiomyopathy.

Dr. Chang also held academic positions at Stanford University, where

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Thu, 03 Sep 2026 07:30:00 -0400

MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer.

Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicine, foundational research, and drug discovery. He joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology.

“CP

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Thu, 03 Sep 2026 07:30:00 -0400

“CP

Eikon Therapeutics to Participate in Investor Conferences in September 2026

Wed, 26 Aug 2026 07:30:00 -0400

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:

Event:12^th Annual Cantor Global Healthcare Conference
Location: New York, NY
Date & Time: September 10, 2026 at 2:10 pm ET
Format: Fireside Chat

Event: The Morgan Stanley 24th Annual Global Healthcare Conference
Location: New

Eikon Therapeutics to Participate in Investor Conferences in September 2026

Wed, 26 Aug 2026 07:30:00 -0400

Event:12^th Annual Cantor Global Healthcare Conference
Location: New York, NY
Date & Time: September 10, 2026 at 2:10 pm ET
Format: Fireside Chat

Event: The Morgan Stanley 24th Annual Global Healthcare Conference
Location: New

Eikon Therapeutics (EIKN) Reiterated at Overweight by Cantor Fitzgerald

Fri, 21 Aug 2026 08:29:05 -0400

Cantor Fitzgerald analyst Imogen Mansfield reiterated an Overweight rating on Eikon Therapeutics Inc. (NASDAQ: EIKN).

The analyst commented, "EIKN is pursuing combinations for EIK1003 paclitaxel, carboplatin/ paclitaxel (both in multiple solid tumors), and abiraterone (in metastatic prostate cancer). EIK1004, EIKN's brain penetrant program, has monotherapy data upcoming at ESMO but EIKN plans to pursue a similar broad combination strategy. This asset has a particularly interesting opportunity in breast cancer, where BRCA mutant disease is at high risk of metastasizing to the brain."

For an analyst ratings summary and ratings history on Eikon Therapeutics Inc. click here. For more ratings news on

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

Tue, 18 Aug 2026 16:15:00 -0400

MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.